“The Panta 2 System is designed to achieve bone healing through appropriate bone fixation and bone compression,” said Brodsky, of the Baylor University Medical Center in Dallas, Texas, and the primary design surgeon of the system. “In my recent use of the new Panta 2 System, it was successful in placing the ankle in the optimal position for healing due to the simplicity, power, and compression of the product.”
TTC Fusion is a reconstructive ankle surgery for severe arthritis and complex deformities in which bone-to-bone contact through compression is paramount for long-term success. Panta 2’s new carbon fiber targeting and compression device offers surgeons an unobstructed view intraoperatively of the Panta 2 Nail for improved visibility for positioning and identification that bone-to-bone contact has been achieved. With up to 12 mm of compression for patients of varying anatomy, the Panta 2 instrumentation and implants are designed to achieve fusion of the TTC joint.
“Integra LifeSciences is dedicated to offering orthopedic surgeons a full continuum-of-care for patients with advanced ankle arthritis,” said Robert T. Davis, Jr., corporate vice president and president of Orthopedic and Tissue Technologies. “The launch of the Panta 2 System is a result of our passion and focus to advance our technologies and improve the quality of life for patients’ post-surgery.”
Integra LifeSciences is a global developer of regenerative technologies, neurosurgical and extremity orthopedic solutions. The company offers a portfolio of brands that include AmnioExcel, Bactiseal, Cadence, Certas, Codman, CUSA, DuraGen, DuraSeal, ICP Express, Integra, MediHoney, MicroFrance, Panta, PriMatrix, Salto Talaris, SurgiMend, TCC-EZ, Titan, and VersaTru.